Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? (UPDATED)
Emergent BioSolutions has secured over $250 million in contract modifications from the ASPR at the U.S. Department of Health and Human Services. The funding ensures the supply of critical medical countermeasures, including Cyfendus for anthrax, ACAM2000 for smallpox, VIGIV for smallpox vaccine complications, and BAT for botulism.